Beyond the Topo-I Rush: Finding Space in a Crowded ADC Landscape
James Turrell’s Twilight Epiphany Skyspace in Houston
As a wave of me-too Topo-I antibody drug conjugates (ADCs) flood the oncology landscape, we interviewed a c-suite executive at Genmab who explains why successful ADC development requires much more than just picking the trendy payload.
There’s a critical look at why Topo-1 molecules alone won’t be enough to guarantee success in this complex and rapidly evolving field.
From the critical importance of antibody internalisation to the game-changing role of linker chemistry, we learn how Genmab is strategically positioning itself in an increasingly crowded space.
The company’s deep expertise in bispecific antibodies may provide unique insights into how future ADC development might evolve beyond traditional formats.
Through their ProfoundBio acquisition and sophisticated antibody platform, we discover why Genmab believes the future lies not just in conventional ADCs, but also in next-generation bispecific modalities, which could reshape how we look at targeted cancer therapy…
To continue reading our latest highlights on oncology new product development including commentary and analysis BSB subscribers can log-in or you can click to access the content.
This content is restricted to subscribers
